Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04514484 · OUTCOME

CD4 Immune Status

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
cells/µL
Interval / dispersion
Full Range
Time frame
At Treatment Cycle 2

What was measured

CD4 immune status at treatment Cycle 2.

Analysis population: Treated patients who provided samples for immune function testing.

Groups in this outcome

Treatment (Cabozantinib S-malate, Nivolumab)

Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Cabozantinib S-malate, Nivolumab)3

Reported measurements

Source class 1
Values in cells/µL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Treatment (Cabozantinib S-malate, Nivolumab)284Not reported245.0635.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        245.0
        upper Limit
        635.0
        value
        284
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
CD4 immune status at treatment Cycle 2.
dispersion Type
Full Range
groups
  1. description
    Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
    id
    OG000
    title
    Treatment (Cabozantinib S-malate, Nivolumab)
param Type
MEDIAN
population Description
Treated patients who provided samples for immune function testing.
reporting Status
POSTED
time Frame
At Treatment Cycle 2
title
CD4 Immune Status
type
SECONDARY
unit Of Measure
cells/µL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice